Andy Jones

Articles

Pharma is moving towards greater patientcentricity – but there are plenty of obstacles and commercial pressures remaining, reports Andrew McConaghie.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.